Fasting period after Rybelsus administration influences clinical benefit
- International Journal of Complementary & Alternative Medicine
Kenji Hayashi, MD,1 Hiroshi Bando, MD,1,2,3 Kazuya Miki, Pharm D,1 Eri Yasuoka, MD,1 Asami Kamoto, Pharm D,1 Tatsuo Yasuoka MD1
PDF Full Text
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been attracted attention for various beneficial effects. Among them, oral semaglutide (Rybelsus) was developed using the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The relationship between the bioavailability and post-dose fasting time period was analyzed. The results showed that i) its bioavailability with drinking 50mL and 120mL of water together was almost similar, ii) bioavailability for 240mL intake was about 2/3 of 50- 120mL, iii) general availability would be about 1.4% for 50-120ml water, and 0.8% for 240mL of water. Tolerability and safety of Rybelsus showed similar results for healthy subjects, patients with renal and/or hepatic impairment. From mentioned above, Rybelsus has been one of the topic agents with characteristic mechanism of SNAC and clinical benefit of GLP-1RA. It will be expected to be applied widely in actual diabetic practice.
Glucagon-like peptide 1 receptor agonist (GLP-1 RA), semaglutide, Rybelsus, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), bioavailability